Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines

Yuan,Tein‑Ming; Liang,Ruei‑Yue; Chueh,Pin  Ju; Chuang,Show‑Mei

doi:10.3892/ol.2015.2900

April-2015 Volume 9 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2015 Volume 9 Issue 4

Full Size Image

Article

Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines

Authors:
- Tein‑Ming Yuan
- Ruei‑Yue Liang
- Pin Ju Chueh
- Show‑Mei Chuang
View Affiliations / Copyright

Affiliations: Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan, R.O.C.
Pages: 1861-1868
|
Published online on: January 27, 2015

https://doi.org/10.3892/ol.2015.2900
Expand metrics +

Abstract

The identification of prognostic markers and establishing their value as therapeutic targets improves therapeutic efficacy against human cancers. Ribophorin II (RPN2) has been demonstrated to be a prognostic marker of human cancer, including breast and pancreatic cancers. The present study aimed to evaluate RPN2 expression in gastric cancer and to examine the possible correlation between RPN2 expression and the response of cells to clinical anticancer drugs, which has received little research attention at present. The gastric cancer AGS, TMC‑1, SNU‑1, TMK‑1, SCM‑1, MKN‑45 and KATO III cell lines were used as a model to elucidate the role of RPN2 in the response of cells to six common chemotherapeutic agents, comprising oxaliplatin, irinotecan, doxorubicin, docetaxel, cisplatin and 5‑fluorouricil. The functional role of RPN2 was assessed by silencing RPN2 using small interfering RNA (siRNA), and the cytotoxicity was determined by an MTS assay and analysis of apoptosis. Molecular events were evaluated by western blotting. All the anticancer drugs were found to exert a concentration‑dependent decrease on the cell survival rate of each of the cell lines tested, although the RPN2 levels in the various cell lines were not directly correlated with responsiveness to clinical anticancer drugs, based on the calculated IC50 values. siRNA‑mediated RPN2 downregulation enhanced cisplatin‑induced apoptosis in AGS cells, but did not markedly decrease the cell survival rates of these cells in response to the tested drugs. Furthermore, RPN2 silencing in MKN‑45 cells resulted in no additional increase in the cisplatin‑induced apoptosis and survival rates. It was also found that RPN2 depletion increased anticancer drug‑mediated cytotoxicity in gastric cancer cell lines. However, the predictive value of RPN2 expression in cancer therapy is questionable in gastric cancer models.

View Figures

View References

1	Davis MP, Dewald GW, Pierre RV and Hoagland HC: Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet. 12:63–71. 1984. View Article : Google Scholar : PubMed/NCBI
2	Löffler C, Rao VV and Hansmann I: Mapping of the ribophorin II (RPN II) gene to human chromosome 20q12-q13.1 by in-situ hybridization. Hum Genet. 87:221–222. 1991. View Article : Google Scholar : PubMed/NCBI
3	Roulston D, Espinosa R III, Stoffel M, Bell GI and Le Beau MM: Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood. 82:3424–3429. 1993.PubMed/NCBI
4	Testa JR, Kinnealey A, Rowley JD, Golde DW and Potter D: Deletion of the long arm of chromosome 20 [del(20)(q11)] in myeloid disorders. Blood. 52:868–877. 1978.PubMed/NCBI
5	Crimaudo C, Hortsch M, Gausepohl H and Meyer DI: Human ribophorins I and II: the primary structure and membrane topology of two highly conserved rough endoplasmic reticulum-specific glycoproteins. EMBO J. 6:75–82. 1987.PubMed/NCBI
6	Hortsch M, Avossa D and Meyer DI: Characterization of secretory protein translocation: ribosome-membrane interaction in endoplasmic reticulum. J Cell Biol. 103:241–253. 1986. View Article : Google Scholar : PubMed/NCBI
7	Kelleher DJ, Kreibich G and Gilmore R: Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein. Cell. 69:55–65. 1992. View Article : Google Scholar : PubMed/NCBI
8	Kelleher DJ and Gilmore R: An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology. 16:47R–62R. 2006. View Article : Google Scholar
9	Kaushal M, Mishra AK, Sharma J, Zomawia E, Kataki A, Kapur S and Saxena S: Genomic alterations in breast cancer patients in betel quid and non betel quid chewers. PLoS One. 7:e437892012. View Article : Google Scholar : PubMed/NCBI
10	Zhu J, He J, Liu Y, Simeone DM and Lubman DM: Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res. 11:2272–2281. 2012. View Article : Google Scholar : PubMed/NCBI
11	Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 14:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
12	De Souza R, Zahedi P, Badame RM, Allen C and Piquette-Miller M: Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther. 10:1289–1299. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K and Baba H: RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer. 107:1233–1238. 2012. View Article : Google Scholar : PubMed/NCBI
14	Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007. View Article : Google Scholar : PubMed/NCBI
15	Stanley LA, Horsburgh BC, Ross J, Scheer N and Wolf CR: Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev. 41:27–65. 2009. View Article : Google Scholar : PubMed/NCBI
16	Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580:998–1009. 2006. View Article : Google Scholar : PubMed/NCBI
17	Chen KG and Sikic BI: Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res. 18:1863–1869. 2012. View Article : Google Scholar : PubMed/NCBI
18	Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE and Gottesman MM: Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 15:62–69. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Related Articles